Dudediligence.

Eli Lilly and Company

LLYNYSE · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Revenue, by quarter
$11.44BSep ’24$13.53BDec ’24$12.73BMar ’25$15.56BJun ’25$17.60BSep ’25$19.29BDec ’25$19.80BMar ’26$22.97BJun ’26
Net income, by quarter
$970.3MSep ’24$4.41BDec ’24$2.76BMar ’25$5.66BJun ’25$5.58BSep ’25$6.64BDec ’25$7.40BMar ’26$7.09BJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue$28.32B$28.54B$34.12B$45.04B$65.18B
Gross profit$21.01B$21.91B$27.04B$36.63B$54.13B
Net income$5.58B$6.24B$5.24B$10.59B$20.64B
Operating cash flow$7.37B$7.59B$4.24B$8.82B$16.81B
Free cash flow$6.06B$5.73B$792.0M$3.76B$8.97B
Cash$3.82B$2.07B$2.82B$3.27B$7.27B
Debt$16.88B$16.24B$25.23B$33.64B$42.50B
Shares outstanding954.1M950.6M949.8M947.9M944.8M